Effect of urate LowEring Agent Febuxostat in Chronic Heart Failure patients with hyperuricemia
Phase of Trial: Phase IV
Latest Information Update: 01 Mar 2019
Price : $35 *
At a glance
- Drugs Febuxostat (Primary)
- Indications Chronic heart failure; Hyperuricaemia
- Focus Therapeutic Use
- Acronyms LEAF-CHF
- 28 Feb 2019 Status changed from recruiting to completed.
- 05 Mar 2015 According to the the University Hospital Medical Information Network - Japan record, status changed from not yet recruiting to recruiting.
- 01 Aug 2014 Planned initiation date changed from 1 Apr 2014 to 1 Aug 2014 as reported by University Hospital Medical Information Network - Japan